A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC)

PURPOSE: Small cell lung cancer (SCLC) is a highly aggressive disease representing 12-13% of total lung cancers, with median survival <2 years. No targeted therapies have proven effective in SCLC. While most patients respond initially to cytotoxic chemotherapies, resistance rapidly emerges, respo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Gaponova, Anna V., Nikonova, Anna S., Deneka, Alexander, Kopp, Meghan C., Kudinov, Alexander E., Skobeleva, Natalia, Khazak, Vladimir, Ogawa, Luisa S., Cai, Kathy Q., Duncan, Kelly E., Duncan, James S., Egleston, Brian L., Proia, David A., Boumber, Yanis, Golemis, Erica A.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5065742/
https://ncbi.nlm.nih.gov/pubmed/27267850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-3068
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items